Skip to main content

NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)

Agency: National Institutes of Health

Assistance Listings
  • 93.321 -- Dietary Supplement Research Program
  • 93.213 -- Research and Training in Complementary and Integrative Health

Archived opportunityLast Updated: May 13, 2026

View version history on Grants.gov

This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA will provide up to two years (R61 phase) of support for milestone-driven testing of bioavailability, pharmacokinetics, and assessment of the natural products effect (i.e., measure of mechanism of action) when used by humans on a biological signature(s). If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may be awarded to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications can design R33 studies to determine how to optimize the impact of the natural product on the biological signature by (1) optimizing the delivery of the natural product by dose or formulation; (2) combining the natural product with another treatment approach that is known to impact the same biological signature; or (3) studying the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R61/R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early-stage clinical testing to determine whether continued clinical research is warranted. This FOA will not support efficacy or e

Eligibility

Eligible applicants

Education

  • Independent school districts
  • Public and state institutions of higher education
  • Private institutions of higher education

Government

  • Federally recognized Native American tribal governments
  • State governments
  • County governments
  • Public and Indian housing authorities
  • City or township governments
  • Special district governments

Miscellaneous

  • Other

Business

  • For-profit organizations other than small businesses
  • Small businesses

Nonprofit

  • Nonprofits non-higher education without 501(c)(3)
  • Nonprofits non-higher education with 501(c)(3)
  • Other Native American tribal organizations

Additional information

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Grantor contact information

Description

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV

Email

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

FBOWebmaster@OD.NIH.GOV

Documents

File nameDescriptionLast updated
PAR-20-218-Full-Announcement.html
PAR-20-218 Full Announcement Text
Jan 20, 2022 02:22 PM UTC

Link to additional information

http://grants.nih.gov/grants/guide/pa-files/PAR-20-218.html

Archived: October 7, 2023

Application process

This site is a work in progress. Go to www.grants.gov to apply, track application status, and subscribe to updates.

Award

$--

Program Funding

--

Expected awards

$--

Award Minimum

$350,000

Award Maximum

Funding opportunity number:

PAR-20-218

Cost sharing or matching requirement:

No

Funding instrument type:

Grant

Opportunity Category:

Discretionary

Opportunity Category Explanation:

--

Category of Funding Activity:

Health

Category Explanation:

--

History

Version:

3

Posted date:

May 20, 2020

Archive date:

October 7, 2023

HHS.gov

An official website of the U.S. Department of Health and Human Services

Looking for U.S. government information and services? Visit USA.gov